TY - JOUR
T1 - Calcium electroporation in three cell lines
T2 - A comparison of bleomycin and calcium, calcium compounds, and pulsing conditions
AU - Frandsen, Stine Krog
AU - Gissel, Hanne
AU - Hojman, Pernille
AU - Eriksen, Jens
AU - Gehl, Julie
PY - 2014/3/1
Y1 - 2014/3/1
N2 - Background Electroporation with calcium (calcium electroporation) can induce ATP depletion-associated cellular death. In the clinical setting, the cytotoxic drug bleomycin is currently used with electroporation (electrochemotherapy) for palliative treatment of tumors. Calcium electroporation offers several advantages over standard treatment options: calcium is inexpensive and may readily be applied without special precautions, as is the case with cytostatic drugs. Therefore, details on the use of calcium electroporation are essential for carrying out clinical trials comparing calcium electroporation and electrochemotherapy. Methods The effects of calcium electroporation and bleomycin electroporation (alone or in combination) were compared in three different cell lines (DC-3F, transformed Chinese hamster lung fibroblast; K-562, human leukemia; and murine Lewis Lung Carcinoma). Furthermore, the effects of electrical pulsing parameters and calcium compound on treatment efficacy were determined. Results Electroporation with either calcium or bleomycin significantly reduced cell survival (p < 0.0001), without evidence of a synergistic effect. Cellular death following calcium or bleomycin treatment occurred at similar applied voltages, suggesting that similar parameters should be applied. At equimolar concentrations, calcium chloride and calcium glubionate resulted in comparable decreases in cell viability. Conclusions Calcium electroporation and bleomycin electroporation significantly reduce cell survival at similar applied voltage parameters. The effect of calcium electroporation is independent of calcium compound. General significance This study strongly supports the use of calcium electroporation as a potential cancer therapy and the results may aid in future clinical trials.
AB - Background Electroporation with calcium (calcium electroporation) can induce ATP depletion-associated cellular death. In the clinical setting, the cytotoxic drug bleomycin is currently used with electroporation (electrochemotherapy) for palliative treatment of tumors. Calcium electroporation offers several advantages over standard treatment options: calcium is inexpensive and may readily be applied without special precautions, as is the case with cytostatic drugs. Therefore, details on the use of calcium electroporation are essential for carrying out clinical trials comparing calcium electroporation and electrochemotherapy. Methods The effects of calcium electroporation and bleomycin electroporation (alone or in combination) were compared in three different cell lines (DC-3F, transformed Chinese hamster lung fibroblast; K-562, human leukemia; and murine Lewis Lung Carcinoma). Furthermore, the effects of electrical pulsing parameters and calcium compound on treatment efficacy were determined. Results Electroporation with either calcium or bleomycin significantly reduced cell survival (p < 0.0001), without evidence of a synergistic effect. Cellular death following calcium or bleomycin treatment occurred at similar applied voltages, suggesting that similar parameters should be applied. At equimolar concentrations, calcium chloride and calcium glubionate resulted in comparable decreases in cell viability. Conclusions Calcium electroporation and bleomycin electroporation significantly reduce cell survival at similar applied voltage parameters. The effect of calcium electroporation is independent of calcium compound. General significance This study strongly supports the use of calcium electroporation as a potential cancer therapy and the results may aid in future clinical trials.
KW - Bleomycin
KW - Calcium electroporation
KW - Cancer
KW - Electrochemotherapy
KW - In vitro
UR - http://www.scopus.com/inward/record.url?scp=84891694302&partnerID=8YFLogxK
U2 - 10.1016/j.bbagen.2013.12.003
DO - 10.1016/j.bbagen.2013.12.003
M3 - Article
C2 - 24342489
AN - SCOPUS:84891694302
SN - 0006-3002
VL - 1840
SP - 1204
EP - 1208
JO - Biochimica et Biophysica Acta - General Subjects
JF - Biochimica et Biophysica Acta - General Subjects
IS - 3
ER -